Press releases

RESULTS OF PHASE I/II CLINICAL STUDY ON THE ACTIVE INGREDIENT OF VALEDIA®

June 9th 2017

VALBIOTIS will present the results of its Phase I/II clinical study on the active ingredient of Valedia®, Totum-63, during the 77th Scientific Sessions of the American Diabetes Association.

Read more

VALBIOTIS INITIAL PUBLIC OFFERING RECORDS HUGE SUCCESS

June 2nd 2017

VALBIOTIS has announced today the huge success of its initial public offering and the admission of its shares for trading on Alternext Paris (ISIN code: FR0013254851 and mnemonic code: ALVAL).

Read more

SEBASTIEN PELTIER, CEO OF VALBIOTIS, PRESENTS HIS VISION OF A DIABETES-FREE WORLD AT L’ÉCHAPPÉE VOLÉE

April 24th 2017

Sébastien Peltier has been selected to share his vision of a diabetes-free world at l’Echappée Volée from 12 to 14 May in Chantilly, France.

Read more

TWO PARTNERSHIP AGREEMENTS TO ASSESS THE EFFECTS OF TOTUM-63, THE ACTIVE INGREDIENT OF VALEDIA®, ON INTESTINAL MICROBIOTA

April 12th 2017

VALBIOTIS has announced the signing of two partnership agreements, one with Biofortis (Merieux NutriSciences), and the other with the Université Catholique de Louvain (Belgium) and Prof. Patrice D. Cani1 (PhD) as part of a program aimed at evaluating the efficacy of TOTUM-63, the active ingredient of Valedia®, on intestinal microbiota.

Read more